RT Journal Article
SR Electronic
T1 The Genetic Determinants and Genomic Consequences of Non-Leukemogenic Somatic Point Mutations
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2024.08.22.24312319
DO 10.1101/2024.08.22.24312319
A1 Weinstock, Joshua S.
A1 Chaudhry, Sharjeel A.
A1 Ioannou, Maria
A1 Viskadourou, Maria
A1 Reventun, Paula
A1 Jakubek, Yasminka A.
A1 Alexander Liggett, L.
A1 Laurie, Cecelia
A1 Broome, Jai G.
A1 Khan, Alyna
A1 Taylor, Kent D.
A1 Guo, Xiuqing
A1 Peyser, Patricia A.
A1 Boerwinkle, Eric
A1 Chami, Nathalie
A1 Kenny, Eimear E.
A1 Loos, Ruth J.
A1 Psaty, Bruce M.
A1 Russell, Tracy P.
A1 Brody, Jennifer A.
A1 Yun, Jeong H.
A1 Cho, Michael H.
A1 Vasan, Ramachandran S.
A1 Kardia, Sharon L.
A1 Smith, Jennifer A.
A1 Raffield, Laura M.
A1 Bidulescu, Aurelian
A1 O’Brien, Emily
A1 de Andrade, Mariza
A1 Rotter, Jerome I.
A1 Rich, Stephen S.
A1 Tracy, Russell P.
A1 Chen, Yii Der Ida
A1 Gu, C. Charles
A1 Hsiung, Chao A.
A1 Kooperberg, Charles
A1 Haring, Bernhard
A1 Nassir, Rami
A1 Mathias, Rasika
A1 Reiner, Alex
A1 Sankaran, Vijay
A1 Lowenstein, Charles J.
A1 Blackwell, Thomas W.
A1 Abecasis, Goncalo R.
A1 Smith, Albert V.
A1 Kang, Hyun M.
A1 Natarajan, Pradeep
A1 Jaiswal, Siddhartha
A1 Bick, Alexander
A1 Post, Wendy S.
A1 Scheet, Paul
A1 Auer, Paul
A1 Karantanos, Theodoros
A1 Battle, Alexis
A1 Arvanitis, Marios
YR 2024
UL http://medrxiv.org/content/early/2024/08/26/2024.08.22.24312319.abstract
AB Clonal hematopoiesis (CH) is defined by the expansion of a lineage of genetically identical cells in blood. Genetic lesions that confer a fitness advantage, such as point mutations or mosaic chromosomal alterations (mCAs) in genes associated with hematologic malignancy, are frequent mediators of CH. However, recent analyses of both single cell-derived colonies of hematopoietic cells and population sequencing cohorts have revealed CH frequently occurs in the absence of known driver genetic lesions. To characterize CH without known driver genetic lesions, we used 51,399 deeply sequenced whole genomes from the NHLBI TOPMed sequencing initiative to perform simultaneous germline and somatic mutation analyses among individuals without leukemogenic point mutations (LPM), which we term CH-LPMneg. We quantified CH by estimating the total mutation burden. Because estimating somatic mutation burden without a paired-tissue sample is challenging, we developed a novel statistical method, the Genomic and Epigenomic informed Mutation (GEM) rate, that uses external genomic and epigenomic data sources to distinguish artifactual signals from true somatic mutations. We performed a genome-wide association study of GEM to discover the germline determinants of CH-LPMneg. After fine-mapping and variant-to-gene analyses, we identified seven genes associated with CH-LPMneg (TCL1A, TERT, SMC4, NRIP1, PRDM16, MSRA, SCARB1), and one locus associated with a sex-associated mutation pathway (SRGAP2C). We performed a secondary analysis excluding individuals with mCAs, finding that the genetic architecture was largely unaffected by their inclusion. Functional analyses of SMC4 and NRIP1 implicated altered HSC self-renewal and proliferation as the primary mediator of mutation burden in blood. We then performed comprehensive multi-tissue transcriptomic analyses, finding that the expression levels of 404 genes are associated with GEM. Finally, we performed phenotypic association meta-analyses across four cohorts, finding that GEM is associated with increased white blood cell count and increased risk for incident peripheral artery disease, but is not significantly associated with incident stroke or coronary disease events. Overall, we develop GEM for quantifying mutation burden from WGS without a paired-tissue sample and use GEM to discover the genetic, genomic, and phenotypic correlates of CH-LPMneg.Competing Interest StatementL.M.R. is a consultant for the TOPMed Administrative Coordinating Center (through Westat). B.M.P. serves on the Steering Committee of the Yale Open Data Access Project funded by Johnson & Johnson. J.Y. reports grant support from Bayer. M.C. reports grant support from Bayer and GSK, Consulting and speaking fees from Illumina and AstraZeneca. A.G.B., P.N, and S.J. are cofounders, equity holders, and on the scientific advisory board of TenSixteen Bio. G.R.A. is an employee of Regeneron Pharmaceuticals and receives salary, stock and stock options as compensation.Funding StatementWhole genome sequencing (WGS) for the Trans-Omics in Precision Medicine (TOPMed) program was supported by the National Heart, Lung and Blood Institute (NHLBI). See Supplementary Information 1 for study omics support information. Centralized read mapping and genotype calling, along with variant quality metrics and filtering were provided by the TOPMed Informatics Research Center (3R01HL-117626-02S1; contract HHSN268201800002I). Phenotype harmonization, data management, sample-identity quality control and general study coordination were provided by the TOPMed Data Coordinating Center (R01HL-120393; U01HL-120393; contract HHSN268201800001I). We thank the studies and participants who provided biological samples and data for TOPMed. The full study-specific acknowledgments are included in Supplementary Cohort Acknowledgements.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethics committee/IRB of Johns Hopkins University gave ethical approval for this workI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesIndividual whole-genome sequence data for TOPMed whole genomes, individual-level harmonized phenotypes and the CHIP variant call sets used in this analysis are available through restricted access via the dbGaP TOPMed Exchange Area available to TOPMed investigators.